Action of elgodipine on atherosclerosis development, cell growth, and oncogene expression in vascular smooth muscle cells

General Pharmacology

Volumn 28, Issue 3, 1997, Pages 463-468

  Del Rio, M ^a   Ruiz, E ^a   Tejerina, T ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

calcium antagonists; cholesterol fed rabbits; elgodipine; oncogene; tissue culture; vascular smooth muscle cell

Indexed keywords

CALCIUM; CALCIUM ANTAGONIST; CHOLESTEROL; ELGODIPINE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CHOLESTEROL DIET; CONTROLLED STUDY; MALE; NONHUMAN; ONCOGENE; ONCOGENE C FOS; ONCOGENE C JUN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT; SMOOTH MUSCLE FIBER; TISSUE LEVEL; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; ARTERIOSCLEROSIS; BLOOD PRESSURE; CALCIUM; CALCIUM CHANNEL BLOCKERS; CELL DIVISION; CELLS, CULTURED; CHOLESTEROL, DIETARY; DIHYDROPYRIDINES; GENE EXPRESSION; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; MALE; MUSCLE, SMOOTH, VASCULAR; PROTO-ONCOGENE PROTEINS; RABBITS; TRIGLYCERIDES;

EID: 0031044510     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(96)00067-5     Document Type: Article

References (26)

1. Berridge M. J. (1975) The interaction of cyclic nucleotides and calcium in the control of cellular activity. In: Advances in Cyclic Nucleotide Research (Edited by Greenegard P. and Robinson P.) Vol. 6, pp. 1-98. Raven Press, New York.
2. Blumlein S. L., Sievers R., Kidd P. and Parmley W. W. (1984) Mechanism of protection from atherosclerosis by verapamil in the cholesterol-fed rabbit. Am. J. Cardiol. 54, 884-889.
3. Boucek M., and Snyderman R. (1976) Calcium influx requirement for human neutrophil chemotaxis: inhibition by lanthanum chloride. Science 193, 905-907.
4. Chomczynski P. and Sacchi N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal. Biochem. 162, 156-159.
5. Chulia T., Del Rio M. and Tejerina T. (1995) Effects of Elgodipine on different blood vessels. Eur. J. Pharmac. (in press).
6. D'Amore P. and Shepro D. (1977) Stimulation of growth and calcium influx in cultured, bovine, aortic endothelial cells by platelets and vasoactive substances. J. Cell. Physiol. 92, 117-184.
7. Del Rio M., Chulia T. and Tejerina T. (1994) Elgodipine, a new 1,4-dihidropyridine compound, inhibits vascular smooth muscle cell proliferation. XIIth International Congress of Pharmacology, Montreal, Quebec, Canada P1.13.062. Can. J. Physiol. Pharmac. 72(suppl. 1), 160.
8. Dole V. P. (1956) A relationship between unesterified fatty acid in plasma and the metabolism of glucose. J. Clin. Invest. 35, 150-154.
9. Fleckenstein A. and Fleckenstein-Grün G. (1980) Cardiovascular protection by calcium antagonists. Eur. Heart J. 1(suppl. B), 15.
10. Fleckenstein A., Frey M., Zorn J. and Fleckenstein-Grün G. (1987) The role of calcium in the pathogenesis of experimental arteosclerosis. TIPS 8, 492-501.
11. Fleckenstein A., Frey M., Thimm F. and Fleckenstein-Grün G. (1990) Excessive mural calcium overload: a predominant causal factor in the development of stenosing coronary plaques in humans. Drugs Ther. 4, 1006-1014.
12. Henry P. D. and Bentley K. I. (1981) Suppression of atherogenesis in cholesterol fed rabbits treated with nifedipine. J. Clin. Invest. 68, 1366-1269.
13. Henry P. D. (1987) Anti-atherosclerotic effects of calcium antagonists: a brief review. Clin. Invest. Med. 10, 601-606.
14. Keogh A. M. and Schroeder J. S. (1990) A review of calcium antagonists and Atherosclerosis. J. Cardiovasc. Pharmac. 16(suppl. 6), S28-S35.
15. Ko Y., Totzke G., Graack G., Heidgen F., Meyer Z. U., Brickwedde M., Düsing R., Vetter H. and Sachinidis A. (1993) Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells. J. Hypertens. 11, 1171-1178.
16. Koibuchi Y., Sakai S., Miura S., Ono T., Shibayama F. and Ohtsuka, M. (1989) Suppression of atherogenesis in cholesterol-fed rabbits treated with nilvadipine, a new vasoselective calcium entry blocker. Atherosclerosis 79, 147-155.
17. Kramsch D. M. and Chan C. T. (1978) The effect of agents interfering with soft tissue calcification and cell proliferation on calcific fibrous fatty plaques in rabbits. Circ. Res. 42, 562-571.
18. Kramsch D. M. and Chan C. T. (1978) The effect of agents interfering with soft tissue calcification and cell proliferation on calcific fibrous fatty plaques in rabbits. Circ. Res. 42, 562-571.
19. Nakao J., Ito H., Ooyama T., Chang W. and Muorota S. (1983) Calcium dependency of arotic smooth muscle cell migration induced by 12-l-hydroxy-5,8,10,14-eicosatetraenoic acid. Atherosclerosis 46, 309-319.
20. Skepper J. N. and Kappagoda C. T. (1992) The effect of concurrent administration of isradipine on the development of fatty streaks in the cholesterol-fed rabbit: a morphometric study. Atherosclerosis 96, 17-31.
21. Sukhatme V. P. (1990) Early transcriptional events in cell growth: the Egr family. J. Am. Soc. Nephrol. 1, 859-866.
22. Sukhatme V. P., Cao X., Chang L. C., Tsai-Morris C. H., Stamenkovich D., Ferreira P. C. P., et al. (1988) A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell 53, 37-43.
23. Tamargo J., Lopez-Sedon J., Delpon E., Gonzalez-Morales A. and De Miguel E. (1991) Cardiovascular effects of the new dihydropyridine derivative elgodipine. Arzneim Forsch/Drug Res. 9, 895-899.
24. Tejerina T., Gonzalez P., Lopez J. and Tamargo J. (1989) An in vitro evaluation of oxodipine (IQB-837) with its derivatives IQB-852, IQB-872 and IQB-875. Proceedings of the 4th International Symposium on Calcium Antagonists, Florencia, p. 256.
25. Weinstein D. B. and Heider J. G. (1987) Antiatherogenic properties of calcium antagonists. Am. J. Cardiol. 59, 163B-172B.
26. Whittington-Coleman P. J. and Carrier O. (1970) Effects of agents altering vascular calcium in experimental atherosclerosis. Atherosclerosis 12, 15-24.